Diazon Pharmaceuticals Overview

  • Founded
  • 2013
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 1

Diazon Pharmaceuticals General Information


Developer of onco-therapeutic drugs intended to offer treatment of metastatic triple-negative breast cancer. The company's drugs contribute an anti-cancer agent, which modulates microtubule structure and dynamics in a distinct way, delivering potent anti-tumor efficacy with an unusual safety profile, including lack of neurotoxicity in pre-clinical models, enabling clinicians to kill cancer cells with improved safety margins compared to the other microtubule targeting agents.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 1010 Sherbrooke Street West
  • Suite 408
  • Montreal, Quebec H3A 2R7
  • Canada
+1 (514) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Diazon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Startup
To view Diazon Pharmaceuticals’s complete valuation and funding history, request access »

Diazon Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
Louise Proulx Ph.D Director
Pierre Beauparlant Ph.D Chief Business Officer
Michael Dixon Chief Financial Officer, President & Board Member
Gordon Shore Ph.D Co-Founder & Chief Scientific Officer
Patrick Harran Ph.D Co-Founder
You’re viewing 5 of 6 executive team members. Get the full list »

Diazon Pharmaceuticals Board Members (2)

Name Representing Role Since
Michael Dixon Self Chief Financial Officer, President & Board Member 000 0000
Robert Mcneil Ph.D Sanderling Ventures Chairman 000 0000
To view Diazon Pharmaceuticals’s complete board members history, request access »

Diazon Pharmaceuticals Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Sanderling Ventures Venture Capital Minority 000 0000 000000 0
To view Diazon Pharmaceuticals’s complete investors history, request access »